Weekly Report: what happened at GLMD last week (0408-0412)?

Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

PriceSmart, Inc. Posted better-than-expected earnings for its second quarter. The company reported quarterly sales of $1.29 billion. PriceSmart shares surged 4.6% to $86.90 in pre-market trading. Marin Software Incorporated shares rose 76.1% after the company announced upgrades to its Microsoft Corp advertising integration.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Marin Software (NASDAQ:MRIN) stock is rocketing more than 67% after upgrading its integration with Microsoft Advertising. Shareholder meetings, clinical updates, an annual report and delisting plans are moving stocks this morning. The biggest pre-market stock movers on Wednesday morning are Marin Software and iCoreConnect.

Madrigal announces US launch of NASH/MASH drug Rezdiffra

Healthcare Madrigal announces US launch of NASH/MASH drug Rezdiffra. The drug is now available in the US through a specialty pharmacy network. Other companies working on therapies for NASH and MASH include Eli Lilly and Novo Nordisk. MadrigAL is the first to receive FDA approval for the treatment of the disease.

Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of Agenus Inc. (NASDAQ:AGEN) fell sharply during Monday's session. Auddia Inc. Shares jumped 231.7% to $4.72. The company announced a 1-for-20 reverse stock split of common stock.

Weekly Report: what happened at GLMD last week (0401-0405)?

Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

Esperion Therapeutics, Inc. Shares rose sharply during today’s pre-market trading. The company presented new data from CLEAR outcomes at ACC. 24 highlighting value of NEXLETOL tablets in diverse populations. Longeveron Inc. And Galmed Pharmaceuticals Ltd. Were among the stocks moving in pre- market trading.

GLMD Stock Earnings: Galmed Pharmaceuticals Misses EPS for Q4 2023

Galmed Pharmaceuticals reported earnings per share of -98 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -32 cents. Galmed pharmaceuticals is a subsidiary of GlaxoSmithKline.

Weekly Report: what happened at GLMD last week (0325-0329)?

Weekly Report: what happened at GLMD last week (0318-0322)?

Galmed Pharmaceuticals Granted Nasdaq Extension

On March 19, Galmed Pharmaceuticals Got Letter From Nasdaq That Granted Co Additional 180 Calendar Day Period To Regain Compliance

BRIEF-Galmed Pharmaceuticals Got Letter From Nasdaq Granted Additional 180 Calendar Day Period To Regain Compliance

Galmed Pharmaceuticals Got Letter From Nasdaq Granted Additional 180 Calendar Day Period To Regain Compliance. The company says Nasdaq granted additional 180 calendar day period to regain compliance. Galmed says it is in compliance with Nasdaq's requirements to be listed on the Nasdaq.

Inventiva Phase 2 study for MASH drug meets primary endpoint

Inventiva Phase 2 study for MASH drug meets primary endpoint. Inventiva's drug candidate lanifibranor met its primary efficacy endpoint in the treatment of patients with MASH/NASH and type 2 diabetes. Last week, Madrigal drug Rezdiffra became the first FDA-approved treatment for the liver disorder.

Weekly Report: what happened at GLMD last week (0311-0315)?

NASH drug market expected to surpass $48B by 2035

Healthcare NASH drug market expected to surpass $48B by 2035. Global therapeutic market catering to the widely prevalent liver disease non-alcoholic steatohepatitis is projected to reach $48.3B. North America is set to generate the lion's share of revenue. Europe is anticipated to record the highest CAGR in the NASH treatment market. Madrigal Pharmaceuticals received FDA approval for first U.S.-approved NASH therapy.

Weekly Report: what happened at GLMD last week (0304-0308)?

Weekly Report: what happened at GLMD last week (0226-0301)?

Weekly Report: what happened at GLMD last week (0219-0223)?

Weekly Report: what happened at GLMD last week (0212-0216)?